United States

Aspen Pharmacare Holdings Ltd (APNJ.J)

APNJ.J on Johannesburg Stock Exchange

24 Mar 2017
Change (% chg)

-142.00 (-0.52%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Aspen Pharmacare says HY normalised HEPS rose 6 pct to 692 cents
Thursday, 9 Mar 2017 12:30am EST 

Aspen Pharmacare Holdings Ltd : HY revenue for group grew 13% to R19,8 billion and normalised headline earnings per share increased by 6% to 692 cents . Results in second half of 2017 financial year will be influenced by strengthening of rand .Says overall stronger underlying performance in second half of 2017 financial year is anticipated.  Full Article

Aspen Pharmacare sees HEPS for six months to Dec.31 up 49-57 pct
Wednesday, 1 Mar 2017 10:00am EST 

Aspen Pharmacare Holdings Ltd : . Sees six months to dec.31 headline earnings per share up 49 pct to 57 pct , between 624.0 to 657.5 cents .Sees six months to dec.31 nheps up 3 pct to 8 pct, between 675.2 to 707.9.  Full Article

Aspen completes acquisition of a portfolio of anaesthetics with GlaxoSmithKline
Wednesday, 1 Mar 2017 02:00am EST 

Aspen Pharmacare Holdings:Aspen Holdings is pleased to announce that this transaction completed.  Full Article

Aspen Pharmacare says GSK sells remaining stake in co
Thursday, 29 Sep 2016 03:05am EDT 

Aspen Pharmacare Holdings Ltd : GSK completed an accelerated bookbuild for disposal of its remaining shareholding in aspen .Disposal in no way affects ongoing collaboration between aspen and GSK in South Africa.  Full Article

GSK gets 477 mln stg gross proceeds from Aspen Pharmacare stake sale
Thursday, 29 Sep 2016 02:54am EDT 

Glaxosmithkline Plc :Gross proceeds of Aspen transaction are equivalent to £477 million.  Full Article

GSK says to sell remaining stake in Aspen Pharmacare
Wednesday, 28 Sep 2016 11:19am EDT 

GlaxoSmithKline Plc : GSK intends to sell remaining holding in Aspen . Intends to sell its remaining stake in Aspen Pharmacare Holdings Ltd . Offer price will be determined by means of an accelerated bookbuild offering process which is to start immediately .Offering is expected to comprise up to 28.2 million Aspen ordinary shares equivalent to 6.2 pct of Aspen's ordinary share capital.  Full Article

Aspen Pharmacare to buy exclusive rights to commercialise AstraZeneca's anaesthetics portfolio
Thursday, 1 Sep 2016 02:00am EDT 

Aspen Pharmacare Holdings Ltd : Had signed an agreement with AstraZeneca whereby AGI will acquire exclusive rights to commercialise astrazeneca's global (excluding USA) anaesthetics portfolio .Transaction was anticipated to complete during Q1 of Aspen's 2017 financial year.  Full Article

Astrazeneca completes Aspen agreement
Thursday, 1 Sep 2016 02:00am EDT 

Astrazeneca Plc : Astrazeneca completes Aspen agreement . Completes commercialisation agreement with Aspen for anaesthetics portfolio .Upfront payment, along with all future milestone and royalty payments, will be reported as externalisation revenue in company's financial statements.  Full Article

Aspen Pharmacare Holdings closes 3 bln euro facilities arrangements
Wednesday, 8 Jun 2016 08:15am EDT 

Aspen Pharmacare Holdings Ltd : Aspen closes eur 3,000,000,000 equivalent facilities arrangements . Initial launch size of eur 1.5 bn for eur facilities was significantly oversubscribed .BofAm, Barclays Bank Plc and ABSA Bank Limited acted as joint coordinators.  Full Article

Aspen signs agreement with ANI Pharma for distribution of HPC injection in US
Tuesday, 17 May 2016 05:00am EDT 

Aspen Pharmacare Holdings Ltd : Agreement with ANI pharmaceuticals for distribution of hydroxyprogesterone caproate injection in US . Aspen Global Incorporated will be responsible for supplying HPC finished dose form .While ANI will be responsible for its marketing and distribution in US..  Full Article

More From Around the Web

UPDATE 1-South Africa's Aspen Pharmacare sees growth in China sales

JOHANNESBURG, March 9 South Africa's Aspen Pharmacare forecasts sales of about 2 billion rand ($152 million) in China over the next 12 months, the drugmaker's chief executive said on Thursday after reporting a 6 percent rise in first-half profit.